.

Make Better Decisions

  • Analyze global market entry opportunities
  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

McKesson
US Department of Justice
Moodys
Dow
Teva
Express Scripts
Merck
Medtronic
Accenture
Boehringer Ingelheim

Generated: December 13, 2017

DrugPatentWatch Database Preview

MITIGARE Drug Profile

« Back to Dashboard

When do Mitigare patents expire, and what generic alternatives are available?

Mitigare is a drug marketed by Hikma Intl Pharms and is included in one NDA. There are five patents protecting this drug and one Paragraph IV challenge.

The generic ingredient in MITIGARE is colchicine. There are sixteen drug master file entries for this compound. Eleven suppliers are listed for this compound. Additional details are available on the colchicine profile page.
Drug patent expirations by year for MITIGARE

Pharmacology for MITIGARE

Medical Subject Heading (MeSH) Categories for MITIGARE

US Patents and Regulatory Information

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Patent Submitted Product Substance Delist Req. Exclusivity Expiration
Hikma Intl PharmsMITIGAREcolchicineCAPSULE;ORAL204820-001Sep 26, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Hikma Intl PharmsMITIGAREcolchicineCAPSULE;ORAL204820-001Sep 26, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Hikma Intl PharmsMITIGAREcolchicineCAPSULE;ORAL204820-001Sep 26, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Hikma Intl PharmsMITIGAREcolchicineCAPSULE;ORAL204820-001Sep 26, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
Hikma Intl PharmsMITIGAREcolchicineCAPSULE;ORAL204820-001Sep 26, 2014RXYesYes► Subscribe► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV (Patent) Challenges for MITIGARE

Drugname Dosage Strength RLD Submissiondate
colchicineCapsules0.6 mgMitigare6/10/2016

« Back to Dashboard

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

UBS
Argus Health
McKinsey
Baxter
Johnson and Johnson
Dow
Daiichi Sankyo
Colorcon
Accenture
Citi

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:

botpot